scholarly journals Histopathological analysis of the reproductive system of male dogs experimentally infected with Toxoplasma gondii

2009 ◽  
Vol 39 (7) ◽  
pp. 2123-2127 ◽  
Author(s):  
Tiago Pereira Arantes ◽  
Welber Daniel Zanetti Lopes ◽  
Roberta Machado Ferreira ◽  
Juliana de Souza Pinto Pieroni ◽  
Vanessa Marigo Rocha Pinto ◽  
...  
Keyword(s):  
Toxoplasma Gondii ◽  
Reproductive System ◽  
Interstitial Fibrosis ◽  
Optical Microscope ◽  
Seminiferous Tubules ◽  
Histopathological Analysis ◽  
Hydropic Degeneration ◽  
Toxoplasmic Infection ◽  
Toxoplasma Gondii Infection ◽  
Histopathological Results

The present research aimed to describe possible histopathological alterations in the reproductive system (testicles and epididymis) of male dogs experimentally infected with Toxoplasma gondii. Canines (n=10) serologically negative for T. gondii were selected and distributed into three experimental groups: GI, 3 inoculated with 2.0 x 10(5)P strain oocysts; GII, 3 infected with 1.0 x 10(6)RH strain tachyzoites; and GIII, 4 control dogs. Antibody research (IFAT) against T. gondii was realized. Toxoplasma gondii infection was confirmed by seroconversion of the 6 males infected with tachyzoites and oocysts from postinoculation day (PID) 7 and 14, respectively. At PID 70, all dogs were submitted to orchiectomy and testicle and epididymis samples were collected and histologically processed for examination under optical microscope. The following alterations were diagnosed: mild and moderate mononuclear inflammatory infiltrate in the epididymis, moderate cellular edema, hydropic degeneration and moderate interstitial fibrosis in seminiferous tubules. The histopathological results in the present research, isolation of T. gondii in testicle and epididymis fragments by immunohistochemistry and results from the literature by other authors in different tissues, all infer that the alterations observed in dogs infected with T. gondii are suggestive of toxoplasmic infection.

scholarly journals Immune CD8+ T Cells Prevent Reactivation of Toxoplasma gondii Infection in the Immunocompromised Host

1999 ◽  
Vol 67 (11) ◽  
pp. 5869-5876 ◽  
Author(s):  
Imtiaz A. Khan ◽  
William R. Green ◽  
Lloyd H. Kasper ◽  
Kathy A. Green ◽  
Joseph D. Schwartzman
Keyword(s):  
T Cells ◽  
Toxoplasma Gondii ◽  
Cell Function ◽  
Immunocompromised Host ◽  
Histopathological Analysis ◽  
Immunosuppressed Patients ◽  
Ifn Γ ◽  
Immunocompromised State ◽  
Toxoplasma Gondii Infection ◽  
Cellular Immune

ABSTRACT Toxoplasma gondii remains a serious cause of morbidity and mortality in individuals that are immunosuppressed, patients with AIDS in particular. The cellular immune response, especially by gamma interferon (IFN-γ)-producing CD8+ T cells, is an essential component of protective immunity against the parasite. In the present study the role of CD8+ T cells during the reactivation of Toxoplasma infection in an immunocompromised murine model was evaluated. Chronically infected mice were challenged with LP-BM5 virus, and the kinetics of CD8+T-cell function was studied. At 10 weeks after viral infection, mice showed obvious signs of systemic illness and began to die. At this stage, CD8+ T cells were unresponsive to antigenic stimulation and unable to kill Toxoplasma-infected targets. IFN-γ production by the CD8+ T cells from dual-infected animals reached background levels, and a dramatic fall in the frequency of precursor cytotoxic T lymphocytes was observed. Histopathological analysis of the tissues demonstrated signs of disseminated toxoplasmosis as a result of reactivation of infection. However, treatment of the dual-infected animals with immune CD8+ T cells at 5 weeks post-LP-BM5 challenge prevented the reactivation of toxoplasmosis, and mice continued to live. Our study for the first time demonstrates a therapeutic role for CD8+ T cells against an opportunistic infection in an immunocompromised state.

The management of acute Toxoplasma gondii infection during pregnancy – literature review

2018 ◽  
Vol 1 (19) ◽  
pp. 16
Author(s):  
Mihai Mitran ◽  
Octavia Velicu ◽  
Roberta Ciobanu ◽  
Diana-Elena Comandașu ◽  
Elvira Brătilă
Keyword(s):  
Toxoplasma Gondii ◽  
Literature Review ◽  
Toxoplasma Gondii Infection

The High Potency of Green Synthesized Copper Nanoparticles to Prevent the Toxoplasma gondii Infection in Mice

2021 ◽  
Author(s):  
Aishah E. Albalawi ◽  
Abdullah D. Alanazi ◽  
Mohamed S. Alyousif ◽  
Azadeh Sepahvand ◽  
Katrin Ebrahimi ◽  
...  
Keyword(s):  
Toxoplasma Gondii ◽  
Copper Nanoparticles ◽  
High Potency ◽  
Toxoplasma Gondii Infection

scholarly journals Protective efficacy by a novel multi-epitope vaccine, including MIC3, ROP8, and SAG1, against acute Toxoplasma gondii infection in BALB/c mice

2021 ◽  
Vol 153 ◽  
pp. 104764
Author(s):  
Samira Dodangeh ◽  
Mahdi Fasihi-Ramandi ◽  
Ahmad Daryani ◽  
Reza Valadan ◽  
Hossein Asgarian-Omran ◽  
...  
Keyword(s):  
Toxoplasma Gondii ◽  
Protective Efficacy ◽  
Epitope Vaccine ◽  
Toxoplasma Gondii Infection

scholarly journals POS0722 HISTOPATHOLOGICAL ANALYSIS OF LUPUS NEPHRITIS INCORPORATING BANFF CRITERIA EMPHASIZES THE IMPORTANCE OF TUBULOINTERSTITIAL CHANGES FOR CREATININE AND PROTEINURIA AT 12 MONTHS AFTER RENAL BIOPSY

2021 ◽  
Vol 80 (Suppl 1) ◽  
pp. 611.1-611
Author(s):  
M. Plüß ◽  
S. Hakroush ◽  
N. Niebusch ◽  
B. Tampe ◽  
P. Korsten
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Nephritis ◽  
Lupus Erythematosus ◽  
Interstitial Fibrosis ◽  
Laboratory Data ◽  
Histopathological Analysis ◽  
Systemic Lupus ◽  
Long Term Outcome ◽  
Banff Classification ◽  
Tubulointerstitial Inflammation

Background:Lupus nephritis (LN) occurs in about 30-60% of patients with systemic lupus erythematosus (SLE). LN is associated with increased mortality. Currently, the diagnosis relies on histopathologic characteristics according to the ISN/RPS classification (1). This classification relies heavily on glomerular changes and may not accurately reflect all changes occurring in LN. For the description of transplanted kidney, the BANFF classification has been established which, in addition to glomerular changes, also incorporates tubular pathologies (2).Objectives:With the present study, we aim to describe histopathologic changes according to the BANFF classification in a single-center cohort of LN patients.Methods:We retrospectively recorded epidemiological, clinical and laboratory data of 58 patients with LN over a ten-year period. Histopathologic diagnoses according to ISN/RPS classification or the former WHO classification were also documented. We then re-analyzed representative kidney samples according to the BANFF classification and performed Spearman rank correlation for BANFF findings and creatinine at biopsy and 12 months as well as proteinuria at biopsy and at 12 months.Results:We analyzed 58 patients with LN. 9 were male, 49 were female. Median age was 38 (15-78) years. According to ISN/RPS, 3 had class I LN, 6 had class II, 14 had class III, 16 had class IV, 6 had class V, and 0 had class VI. Median eGFR at biopsy was 60 ml/min/1.73m2 (13-137). According to the BANFF classification, tubulointerstitial inflammation (ti) was associated with creatinine at 12 months. Proteinuria at 12 months was associated with interstitial fibrosis (ci) (Figure 1).Conclusion:In LN, the current ISN/RPS classification puts emphasis on glomerular changes. Nevertheless, for the long-term outcome, tubulointerstitial changes (tubulointerstitial inflammation and interstitial fibrosis) may at least be as important as glomerular changes. These findings have to be corroborated in larger cohorts with prespecified renal endpoints.References:[1]Weening et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. JASN 2004.[2]Jeong HY. Diagnosis of renal transplant rejection: Banff classification and beyond. Kidney Res Clin Pract 2020.Disclosure of Interests:Marlene Plüß: None declared, Samy Hakroush: None declared, Noah Niebusch: None declared, Björn Tampe: None declared, PETER KORSTEN Speakers bureau: Abbvie, Pfizer, Chugai, Sanofi, Boehringer-Ingelheim, GSK, Novartis, Consultant of: Abbvie, Pfizer, Chugai, Sanofi, Boehringer-Ingelheim, GSK, Novartis, Lilly, Gilead, Grant/research support from: GSK

Sign in / Sign up

Export Citation Format

Share Document